[go: up one dir, main page]

HUP9802999A2 - N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény - Google Patents

N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény

Info

Publication number
HUP9802999A2
HUP9802999A2 HU9802999A HUP9802999A HUP9802999A2 HU P9802999 A2 HUP9802999 A2 HU P9802999A2 HU 9802999 A HU9802999 A HU 9802999A HU P9802999 A HUP9802999 A HU P9802999A HU P9802999 A2 HUP9802999 A2 HU P9802999A2
Authority
HU
Hungary
Prior art keywords
aminoindan
propargyl
pharmaceutical composition
composition containing
alkaline
Prior art date
Application number
HU9802999A
Other languages
English (en)
Inventor
Tirtsah Berger Peskin
Fanny Caciularu
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11068003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9802999(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HUP9802999A2 publication Critical patent/HUP9802999A2/hu
Publication of HUP9802999A3 publication Critical patent/HUP9802999A3/hu
Publication of HU225859B1 publication Critical patent/HU225859B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely hatóanyagként racém,S(-) és/vagy R(+)-N-prőpargil-1-aminő-indán vagy ezek farmakőlógiailagalkalmazható sói közül megválasztőtt vegyületet és legalább 60 tömeg%mennyiségben legalább egy, pentahidrőxi-alkőhől és/vagy hexahidrőxi-alkőhől közül megválasztőtt alkőhőlt tartalmaz, és a mőnő-aminőőxidázenzim B-főrmájának szelektív irreverzíbilis inhibitőra, amelyfelhasználható pl. a Parkinsőn-kór kezelésére. ŕ
HU9802999A 1995-09-20 1996-09-18 Pharmaceutical composition containing r(+)-n-propargyl-1-aminoindan HU225859B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11535795A IL115357A (en) 1995-09-20 1995-09-20 Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
PCT/IL1996/000115 WO1997012583A2 (en) 1995-09-20 1996-09-18 Stable compositions containing n-propargyl-1-aminoindan

Publications (3)

Publication Number Publication Date
HUP9802999A2 true HUP9802999A2 (hu) 1999-04-28
HUP9802999A3 HUP9802999A3 (en) 1999-05-28
HU225859B1 HU225859B1 (en) 2007-11-28

Family

ID=11068003

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802999A HU225859B1 (en) 1995-09-20 1996-09-18 Pharmaceutical composition containing r(+)-n-propargyl-1-aminoindan

Country Status (13)

Country Link
US (1) US6126968A (hu)
EP (1) EP0858328B1 (hu)
JP (1) JP4108750B2 (hu)
AT (1) ATE362755T1 (hu)
AU (1) AU728524B2 (hu)
CA (1) CA2232310C (hu)
DE (1) DE69637096T2 (hu)
DK (1) DK0858328T3 (hu)
ES (1) ES2287940T3 (hu)
HU (1) HU225859B1 (hu)
IL (1) IL115357A (hu)
PT (1) PT858328E (hu)
WO (1) WO1997012583A2 (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL149308A0 (en) 1999-10-27 2002-11-10 Teva Pharma Use of 1-aminoindan derivatives for treatment of manic disorders
ES2588780T3 (es) 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
AU2004324858B2 (en) * 2004-11-10 2009-12-10 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CN103494766A (zh) * 2004-11-24 2014-01-08 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006089164A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
KR20180026580A (ko) 2005-02-23 2018-03-12 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
BRPI0620659A2 (pt) 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
MX2009006252A (es) * 2006-12-14 2009-10-13 Teva Pharma Sal de tanato de rasagilina.
RS52183B (en) * 2006-12-14 2012-10-31 Teva Pharmaceutical Industries, Ltd. CRYSTAL SOLID RAZAGILINE BASE
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CA2711817A1 (en) * 2008-01-11 2009-07-16 Teva Pharmaceutical Industries Ltd. Rasagiline formulations, their preparation and use
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
US20110117200A1 (en) * 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
AU2009258151A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for Parkinson's disease modification
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
US7968749B2 (en) * 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2403485A2 (en) 2009-03-05 2012-01-11 Sandoz AG Pharmaceutical composition containing rasagiline mesylate
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
EA023786B1 (ru) 2010-04-30 2016-07-29 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальные композиции на основе пропиниламиноиндана
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
CA2806737A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
HK1200314A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceuticals Usa, Inc. R(+)-n-methyl-propargyl-aminoindan
KR20140090996A (ko) * 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
MX343986B (es) 2012-03-21 2016-12-01 Synthon Bv Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
ES2502140T1 (es) * 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
CN115400090A (zh) * 2022-10-09 2022-11-29 北京新领先医药科技发展有限公司 一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
SI0814789T2 (sl) * 1995-03-02 2008-04-30 Scherer Technologies Inc R P Farmacevtske zmesi, ki obsegajo inhibitorje monoamin oksidaze b

Also Published As

Publication number Publication date
US6126968A (en) 2000-10-03
AU6942796A (en) 1997-04-28
WO1997012583A2 (en) 1997-04-10
EP0858328A4 (en) 2001-07-11
IL115357A0 (en) 1995-12-31
DK0858328T3 (da) 2007-09-03
EP0858328B1 (en) 2007-05-23
ATE362755T1 (de) 2007-06-15
IL115357A (en) 2000-01-31
EP0858328A2 (en) 1998-08-19
ES2287940T3 (es) 2007-12-16
AU728524B2 (en) 2001-01-11
HU225859B1 (en) 2007-11-28
JP4108750B2 (ja) 2008-06-25
WO1997012583A3 (en) 1997-06-05
PT858328E (pt) 2007-08-20
HUP9802999A3 (en) 1999-05-28
JPH11512736A (ja) 1999-11-02
CA2232310C (en) 2008-01-08
DE69637096D1 (de) 2007-07-05
DE69637096T2 (de) 2008-01-31
CA2232310A1 (en) 1997-04-10

Similar Documents

Publication Publication Date Title
HUP9802999A2 (hu) N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény
DK0889875T3 (da) Cycloproylalkansyrederivater
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
HUP9802221A2 (hu) Parazitaellenes hatású markfortin- és paraherkvamidszármazékok
CA2219742A1 (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
HUP0104131A2 (hu) Aminnal reakcióra képes egy vagy több aktív összetevőt tartalmazó készítmények
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
CA2340052A1 (en) Pharmaceutical compositions containing lipase inhibitors and chitosan
CA2216796A1 (en) Quinazoline derivatives
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
WO2000002542A3 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
EP0391002A3 (en) Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid
CA2214026A1 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR960006915A (ko) 췌장염의 치료 조성물
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
BR9812085A (pt) "método para a sìntese de derivados de quinolina"
HUP0202324A2 (hu) Prukaloprid orális oldat
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
ATE213410T1 (de) Diclofenac/gamma-cyclodextrin klathrat komponente
BR9707770C1 (pt) Tifluzamida com eficácia aperfeiçoada
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
DK0805817T3 (da) Thiolderivater med metallopeptidaseinhiberende aktivitet